![]() | |
Combination of | |
---|---|
Abacavir sulfate | Nucleoside analogue reverse transcriptase inhibitor |
Lamivudine | Nucleoside analogue reverse transcriptase inhibitor |
Zidovudine | Nucleoside analogue reverse transcriptase inhibitor |
Clinical data | |
Trade names | Trizivir |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a616051 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
KEGG | |
NIAID ChemDB | |
![]() ![]() |
Abacavir/lamivudine/zidovudine, sold under the brand name Trizivir, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[2][3][4] It contains three reverse transcriptase inhibitors patented by GlaxoSmithKline and marketed by a joint venture with Pfizer, ViiV Healthcare:[5]
It is indicated in the treatment of AIDS/HIV-1.[2] For this purpose, the combination is very useful in pregnant women to decrease the risk of mother-to-child transmission.[6]
The most common effects include headache and nausea (feeling sick).[3]
Abacavir/lamivudine/zidovudine was approved for use in the United States and the European Union in 2000.[7][3] In December 2013, Lupin Limited launched a generic version of abacavir/lamivudine/zidovudine.[8][9][10]